Ono Venture Investment (OVI) is the corporate venture capital arm of Ono Pharmaceutical Co., Ltd., headquartered in South San Francisco. It invests in early-stage biotech and life sciences startups focused on innovative therapeutic drug targets, oncology, immunology, and neurology.
44% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $71.5M (across 14 rounds with reported amounts).
Portfolio
13
Fund Size
—
Top Stage
Series B
Last 12 Mo
1
Team
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
16 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Mediar | Series B | $76M | Jan 2026 |
 Alchemab Therapeutics | Series A | $32M | Sep 2025 |
 Mozart Therapeutics | Series A | $25M | Jun 2023 |
| VViolet Therapeutics Inc. | Seed | $10.6M | May 2023 |
| SSwitch Therapeutics | Unknown | $52M | Jan 2023 |
 Arbor Biotechnologies | Series B | $215M | Nov 2021 |
 Immunitas Therapeutics | Series B | $58M | Aug 2021 |
| IImmunitas | Series B | $58M | Aug 2021 |
| IImmunitas | Series B | $58M | Jan 2021 |
 Arbor Biotechnologies | Series B | $215M | Jan 2021 |
| MMediar Therapeutics | Seed | — | Jan 2019 |
 AIRNA | Series A | $60M | — |
| CCasma Therapeutics | Series C | $46M | — |
 Violet | Seed | $10.6M | — |
| Mediar | Series A | $85M | — |
| MMediar Therapeutics | Series A | — | — |
Top Co-Investors
Sofinnova Partners5 shared
Pfizer Ventures5 shared
ARCH Venture Partners4 shared
Mirae Asset4 shared
Novartis Venture Fund4 shared
Mass General Brigham Ventures4 shared
Alexandria Venture Investments3 shared
Leaps by Bayer3 shared
Longwood Fund3 shared
Agent Capital3 shared
BrightEdge3 shared
Solasta Ventures3 shared
M Ventures3 shared
Eli Lilly and Company3 shared
Tao Capital Partners2 shared
Illumina Ventures2 shared
Tekla Capital Management2 shared
T. Rowe Price2 shared
S322 shared
Last updated: 20 October 2026